PharmacyCodes



Toremifeno [Spanish] en es it fr

Toremifeno [Spanish] Brand names, Toremifeno [Spanish] Analogs

Toremifeno [Spanish] Brand Names Mixture

  • No information avaliable

Toremifeno [Spanish] Chemical_Formula

C26H28ClNO

Toremifeno [Spanish] RX_link

http://www.rxlist.com/cgi/generic2/toremifene.htm

Toremifeno [Spanish] fda sheet

http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=151

Toremifeno [Spanish] msds (material safety sheet)

Toremifeno [Spanish] Synthesis Reference

R. J. Toivola et al., Eur. pat. Appl. 95,875; U.S. pat. 4,696,949 (1983, 1087 both to Farmos)

Toremifeno [Spanish] Molecular Weight

405.959 g/mol

Toremifeno [Spanish] Melting Point

108-110 oC

Toremifeno [Spanish] H2O Solubility

No information avaliable

Toremifeno [Spanish] State

Solid

Toremifeno [Spanish] LogP

6.725

Toremifeno [Spanish] Dosage Forms

Tablet

Toremifeno [Spanish] Indication

For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors

Toremifeno [Spanish] Pharmacology

Toremifene is an antineoplastic hormonal agent primarily used in the treatment of advanced breast cancer. Toremifene is a nonsteroidal agent that has demonstrated potent antiestrogenic properties in animal test systems. The antiestrogenic effects may be related to its ability to compete with estrogen for binding sites in target tissues such as breast. Toremifene inhibits the induction of rat mammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression of already established DMBA-induced tumors. In this rat model, Toremifene appears to exert its antitumor effects by binding the estrogen receptors. In cytosols derived from human breast adenocarcinomas, Toremifene competes with estradiol for estrogen receptor protein.

Toremifeno [Spanish] Absorption

Well absorbed

Toremifeno [Spanish] side effects and Toxicity

No information avaliable

Toremifeno [Spanish] Patient Information

Patient Information:

Vaginal bleeding has been reported in patients using Toremifene. Patients should be informed about
this and instructed to contact their physician if such bleeding occurs.

Patients with bone metastases should be informed about the typical signs and symptoms of hypercalcemia
and instructed to contact their physician for further assessment if such signs or symptoms occur.

Toremifeno [Spanish] Organisms Affected

Humans and other mammals